Ototoxicity is damage to the inner ear caused by medications, chemicals, or radiation, and it can result in hearing loss, tinnitus, or balance problems that range from barely noticeable to profound and permanent. Hundreds of drugs carry some level of ototoxic risk, but the worst offenders are a handful of medication classes used in cancer treatment, serious infections, and critical care. The damage typically targets the delicate sensory hair cells of the cochlea or the vestibular organs, and because mature mammals cannot regrow those cells, the loss is usually irreversible. What makes ototoxicity especially frustrating is that it often goes undetected until it has already progressed beyond the point where a treatment change could help.
The Drugs Most Likely to Cause Permanent Hearing Loss
Cisplatin, a platinum-based chemotherapy drug used against a wide range of cancers, is the most thoroughly studied ototoxic medication. Once cisplatin enters the cochlea’s sensory hair cells, it triggers a cascade of oxidative stress, DNA damage, and dysfunction in mitochondria that ultimately kills the cells through several forms of programmed cell death.1PubMed. Cisplatin-induced ototoxicity: From signaling network to therapeutic targets The drug also generates reactive oxygen species in the surrounding inner ear tissue, compounding the damage.2PubMed Central. Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies What makes cisplatin particularly insidious is that it stays in the cochlea indefinitely rather than clearing out the way it does from most other tissues.3PubMed. Manipulating the blood labyrinth barrier with mannitol to prevent cisplatin-induced hearing loss
Aminoglycoside antibiotics, including gentamicin, tobramycin, and amikacin, are another major category. These drugs are reserved for serious, often life-threatening infections because of their known toxicity profile. Their ototoxic effects are permanent and stem from direct damage to inner ear cells through multiple overlapping pathways.4PubMed Central. Aminoglycosides-Related Ototoxicity: Mechanisms, Risk Factors, and Prevention in Pediatric Patients Aminoglycosides tend to hit different parts of the inner ear depending on the specific drug. Gentamicin, for instance, preferentially damages the vestibular system (responsible for balance), while amikacin targets the cochlea (responsible for hearing). This distinction matters clinically, because a patient on gentamicin might first notice dizziness or oscillopsia, the unsettling visual bouncing that happens when the vestibular-ocular reflex is impaired, rather than hearing changes.5PubMed Central. Prevention of Severe Vestibular Hypofunction after Systemic Gentamicin
Drugs with Reversible Effects
Not all ototoxic drugs cause permanent damage. Loop diuretics like furosemide and ethacrynic acid, commonly used for heart failure and severe fluid retention, work on the inner ear through a completely different mechanism than chemotherapy drugs. They cause swelling in a structure called the stria vascularis, the tissue that maintains the electrochemical environment the cochlea needs to convert sound into nerve signals. The damage appears to begin with a shutdown of blood flow to the cochlear wall, leading to oxygen deprivation, and the ion transport problems follow from there.6PubMed Central. Ototoxic effects and mechanisms of loop diuretics The good news is that loop diuretic ototoxicity is usually reversible once the drug is stopped or the dose is lowered, because the hair cells themselves are not destroyed. The bad news is that loop diuretics are frequently given alongside aminoglycosides or cisplatin in hospital settings, and the combination can be far worse than either drug alone.
Aspirin and other salicylates at high doses are another classic example of reversible ototoxicity. They cause a characteristic flat hearing loss and tinnitus that typically resolves within a day or two of stopping the drug. At the cellular level, acute salicylate exposure reduces the cochlea’s ability to generate certain types of sound-related electrical signals, with the effect strongest at low and very high frequencies and relatively sparing the mid-range, which interestingly matches the pitch of the tinnitus people report.7PubMed Central. Review of salicylate-induced hearing loss, neurotoxicity, tinnitus and neuropathophysiology At the doses most people take for headaches, ototoxic effects are rare. The risk climbs steeply at the sustained high doses sometimes used for inflammatory conditions.
Medications You Might Not Suspect
Beyond the well-known categories, some less obvious drugs carry ototoxic potential. A recent study examined PDE5 inhibitors, the class of drugs used for erectile dysfunction, and found that users had significantly poorer hearing thresholds on extended high-frequency testing compared to controls. Intriguingly, the hearing deficits were present even before taking the medication, suggesting the underlying vascular conditions associated with erectile dysfunction may predispose people to hearing vulnerability. Post-medication, their thresholds deteriorated further.8PubMed Central. A follow-up Study of Effect of PDE5i Drugs on Extended High-frequency Hearing This is still early-stage research, and nobody is suggesting these drugs should be avoided on hearing grounds alone. But it illustrates how ototoxicity can hide in drug classes that clinicians and patients are not watching closely.
Radiation therapy for head-and-neck tumors and vestibular schwannomas (tumors on the hearing and balance nerve) can also cause sensorineural hearing loss, though the mechanism is different from drug-induced damage. No firm threshold dose to the cochlea has been identified that reliably predicts whether hearing loss will occur, which makes dose planning a balancing act between tumor control and hearing preservation.9PubMed Central. Radiation therapy and hearing loss
When Noise and Chemicals Gang Up
One of the most underappreciated aspects of ototoxicity is how environmental noise amplifies chemical damage to the ear. Workers in industrial settings who are exposed to solvents like toluene, xylene, or styrene face heightened risk of hearing loss even when solvent levels and noise levels are individually below the limits considered safe.10PubMed Central. Combined exposure to noise and ototoxic solvents: contributions to the revision of legal limits based on the literature Moderate noise levels also speed up and worsen ototoxicity from aminoglycosides and cisplatin.11PubMed Central. Potentiation of Chemical Ototoxicity by Noise This is a real gap in occupational health policy, because workplace hearing conservation programs and chemical exposure limits are typically set independently, as if workers are only being hit by one threat at a time. If you are on an ototoxic medication and your job involves loud machinery or industrial solvents, the risk is more than additive.
Genetic Vulnerability
Some people are genetically predisposed to ototoxicity, particularly from aminoglycosides. The best-documented culprits are mutations in the mitochondrial 12S rRNA gene, especially the A1555G and C1494T variants. A systematic review found that these mutations were identified across all 25 studies it examined, with the A1555G mutation emerging as the primary genetic driver of aminoglycoside-induced hearing loss.12PubMed. Genetic susceptibility to aminoglycoside ototoxicity People carrying these mutations can develop severe, permanent hearing loss from even a single standard dose of an aminoglycoside, a reaction that would be unusual in someone without the variant.
These mutations are inherited maternally through mitochondrial DNA, and many carriers have perfectly normal hearing until they encounter the triggering drug. A large neonatal screening study in Beijing found that the combined incidence of these aminoglycoside-susceptibility mutations was about 0.23% among the population screened.13PubMed Central. A cohort study of neonatal hearing testing and genetic screening for variants associated with susceptibility to aminoglycoside antibiotic-induced hearing loss in Beijing, China That sounds small, but in a country that administers millions of courses of aminoglycosides, it translates to a meaningful number of people at risk. Genetic screening before aminoglycoside use is becoming more common in neonatal and pediatric settings, though it is still far from universal.
Why Standard Hearing Tests Miss Early Damage
Ototoxic hearing loss almost always starts in the highest frequencies and works its way down into the speech range. Standard audiometry only tests up to about 8 kHz, but the earliest damage shows up between 9 and 16 kHz, frequencies most people never think about because they are above the range of everyday conversation. Extended high-frequency audiometry, which tests those upper ranges, catches ototoxic shifts much sooner. In one longitudinal study of patients receiving drug-resistant tuberculosis treatment, extended high-frequency testing detected ototoxicity in roughly 86% of patients after treatment, compared to about 48% detected by conventional audiometry.14PubMed. Extended High-Frequency Audiometry for Ototoxicity Monitoring: A Longitudinal Evaluation of Drug-Resistant Tuberculosis Treatment Pilot data from children undergoing platinum chemotherapy tell a similar story: changes in the extended high frequencies and in otoacoustic emissions, sounds generated by healthy outer hair cells, appear before conventional audiometry picks up anything abnormal.15PubMed. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions
Monitoring programs for patients on ototoxic medications vary widely in practice. Published guidelines recommend baseline testing before treatment begins, periodic monitoring during treatment, and follow-up testing afterward, using a combination of conventional and extended high-frequency audiometry plus otoacoustic emissions where possible.16PubMed Central. Monitoring Protocols for Cochlear Toxicity In reality, many cancer treatment centers still rely solely on conventional audiometry, and some do not monitor hearing at all unless the patient complains. This is a missed opportunity, because detecting damage early can prompt a dose adjustment or drug switch before the hearing loss reaches frequencies that affect daily communication.
The Stakes Are Higher for Children
Ototoxicity carries distinct consequences for children, particularly those under five. A child still developing language and social skills can be set back significantly by high-frequency hearing loss, even mild loss that would be a minor nuisance for an adult. As survival rates for pediatric cancers have improved, the long-term effects of treatment-related hearing loss on academic achievement and speech and language development have become an increasingly important concern.17PubMed. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development Studies of pediatric cancer survivors with ototoxicity-related hearing loss report meaningful impacts on quality of life across medical, audiological, psychological, and educational dimensions.18PubMed. Ototoxicity-induced hearing loss and quality of life in survivors of paediatric cancer
For adult cancer survivors, the consequences look different but remain substantial. A literature review of people living beyond platinum chemotherapy found that hearing loss and tinnitus cause communication difficulties and social withdrawal, while chemotherapy-related balance damage increases the risk of falls. Depression and anxiety were consistently associated with ototoxicity, and many survivors reported disruptions to employment and everyday tasks.19PubMed Central. The long-term impacts of hearing loss, tinnitus and poor balance on the quality of life of people living with and beyond cancer after platinum-based chemotherapy: a literature review Qualitative research with these survivors highlights a specific kind of distress: the fear that hearing loss or tinnitus will continue to worsen, layered on top of the already complex emotional landscape of cancer survivorship.20PubMed Central. The impact of chemotherapy-induced inner ear damage on quality of life in cancer survivors: a qualitative study
Protection Strategies That Exist Today
The most significant advance in preventing cisplatin-induced hearing loss is sodium thiosulfate, a drug that scavenges the reactive oxygen species cisplatin produces. Two major randomized trials in children showed striking results. In one, hearing loss of any grade occurred in about a third of children receiving sodium thiosulfate alongside cisplatin, compared to about 63% in the cisplatin-only group, a roughly 48% lower incidence.21PubMed Central. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss In the other trial, hearing loss was identified in about 29% of the sodium thiosulfate group compared to about 56% of controls.22The Lancet Oncology. Sodium thiosulfate as an otoprotectant against cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, open-label, phase 3 trial Crucially, cancer survival rates were not compromised by the addition of sodium thiosulfate, which had been the central worry. These results were strong enough to lead to regulatory approval of sodium thiosulfate for this use in pediatric patients.
Adjusting how cisplatin is dosed is another practical lever. A study of over 560 patients with head and neck cancer compared lower-dose weekly cisplatin to the standard higher-dose schedule given every three weeks. The weekly approach roughly halved the rate of clinically significant hearing loss, with grade 2 or worse ototoxicity occurring in 18% of the weekly group versus 50% of the three-week group, and two-year survival was the same between groups.23PubMed Central. Lower, more frequent cisplatin dosing minimizes hearing loss in head and neck cancer This kind of schedule modification does not require a new drug and can be implemented with existing infrastructure, which makes it a pragmatic option even in settings where sodium thiosulfate is not available.
Animal studies have also explored locally delivered steroids. In guinea pigs, injecting dexamethasone through the eardrum before cisplatin treatment showed a significant protective effect on hearing, and the injection itself caused no harm to the ear.24PubMed. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs This approach has not yet translated into standard clinical practice for ototoxicity prevention, but intratympanic steroid injection is already a routine procedure in otolaryngology for other conditions like sudden hearing loss, so the delivery method is well understood.
Why Mammals Cannot Regrow What They Lose
The reason ototoxic hearing loss is permanent in humans comes down to a biological limitation that separates mammals from many other vertebrates. Birds, fish, and amphibians can regenerate lost hair cells. In birds, neighboring supporting cells reactivate, divide, and differentiate into new hair cells that restore hearing within weeks.25PubMed Central. Anatomical and molecular insights into avian inner ear sensory hair cell regeneration Mature mammals cannot do this. Once hair cells die, the supporting cells that surround them do not spontaneously convert into replacements.26PubMed Central. Hair Cell Regeneration: From Animals to Humans
This has made hair cell regeneration one of the most actively pursued goals in hearing research. Gene therapy using a gene called ATOH1, which plays a key role in hair cell development, has shown that new hair cells can be coaxed into existence in the damaged mammalian cochlea. In guinea pigs deafened by aminoglycosides, ATOH1 gene therapy produced new cells that expressed multiple hair cell proteins. However, these cells did not develop a full set of synaptic connections, and hearing function was not restored.27PLoS ONE. Hair Cell Regeneration after ATOH1 Gene Therapy in the Cochlea of Profoundly Deaf Adult Guinea Pigs More recent work using engineered viral vectors to deliver ATOH1 has produced large numbers of new hair cells in the cochlea, and some of these cells appeared to be at different stages of maturation, suggesting a regenerative process was underway rather than just a burst of initial cell conversion.28Signal Transduction and Targeted Therapy. AAV-ie-K558R mediated cochlear gene therapy and hair cell regeneration
The gap between producing cells that look like hair cells and producing cells that actually restore hearing remains the central challenge. Hearing requires hair cells to be precisely positioned, correctly oriented, and synaptically connected to auditory nerve fibers. Generating the cells is a necessary first step, but wiring them into a functional circuit is a problem of a different order. Several biotech companies are pursuing clinical trials of regenerative approaches, though none has yet demonstrated hearing restoration in humans. For now, preventing ototoxicity remains far more effective than trying to reverse it.
The Blood-Labyrinth Barrier
The inner ear has its own version of the blood-brain barrier, called the blood-labyrinth barrier, which controls what gets in and out of the cochlear fluids. This barrier is part of the reason cisplatin is so damaging: the drug crosses into the cochlea but does not clear back out efficiently, allowing it to accumulate over time and continue harming cells long after the infusion is over. Researchers have explored whether manipulating this barrier could help. One approach uses mannitol, a diuretic that temporarily increases barrier permeability, in hopes of letting cisplatin wash out more quickly or allowing protective drugs to enter more easily.29PubMed. Manipulating the blood labyrinth barrier with mannitol to prevent cisplatin-induced hearing loss This is still experimental, but it represents a fundamentally different approach to the problem: rather than trying to counteract the damage cisplatin causes, it aims to reduce the drug’s residence time in the ear. If it works, the cochlea would simply be exposed to less cisplatin overall, sidestepping the toxicity rather than fighting it after the fact.